Search
Page with Layout
Bakin Lab Publications
… B, Foster BA, Rajan P, Attwood K, Chatley S, Iyer R, Fountzilas C, Bakin AV. Citation: Cell Rep Med. 2024 Mar … Smith B, Melnick M, Eng KH, Melendy T, Park BH, Iyer R, Fountzilas C, Bakin AV. Citation: Commun Biol. 2021 Jul …
Blog Post
What's New in Pancreatic Cancer Research?
… to treat it. “We should always have hope,” says Christos Fountzilas, MD, FACP , Department of Medical Oncology at … existing therapy. Some of the latest developments that Dr. Fountzilas considers exciting are new agents that target the … efforts from basic and clinical cancer researchers, Dr. Fountzilas explains. “Blocking a single pathway is not …
News
Roswell Park Clinical Trials Add Beta Blocker to Arsenal Against Esophageal Cancer
… chemotherapy, and it becomes progressive.” Dr. Christos Fountzilas “Roswell Park is at the forefront of research on … and radiation in those patients,” says Christos Fountzilas, MD, FACP , Co-Leader of the Gastrointestinal … chemotherapy, and it becomes progressive.” Dr. Christos Fountzilas “Roswell Park is at the forefront of research on …
Blog Post
Can a commonly prescribed blood pressure drug improve survival for patients with esophageal cancer?
… and radiation in those patients,” says Christos Fountzilas, MD, FACP , Co-Leader of the Gastrointestinal … Early Phase Clinical Trials Program at Roswell Park. Dr. Fountzilas was co-author of an article in the journal Lancet … cancer.” 04/03/2023 - 12:29 Esophageal cancer Q&A with Dr. Fountzilas New immunotherapy-based treatments for esophageal …
News
Roswell Park Study First to Show Two-Drug Combination Selectively Targets p53-Mutant Cancers
… in the United States,” notes study co-author Christos Fountzilas, MD, FACP , Co-Leader of the Gastrointestinal … Recognizing the need for better therapeutic options, Dr. Fountzilas and his colleague, Andrei V. Bakin, PhD , … for selective targeting of p53-mutant cancers,” Dr. Fountzilas adds. “Of note, while PARP inhibitors are approved …
Clinical Trial
HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects with Locally Advanced or Metastatic Solid Tumors
… with Locally Advanced or Metastatic Solid Tumors II Fountzilas, Christos This is a proof-of-concept study …
Clinical Trial
A Phase I Study of Trifluridine/ Tipiracil plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers
… Polymerase Inhibitor Talazoparib in Advanced Cancers I Fountzilas, Christos This phase I trial investigates the side …
Hematology and Medical Oncology Program Faculty
… Medical Oncology Tessa Faye Flores, MD Prevention Christos Fountzilas, MD, FACP Medical Oncology Mark Frattini, MD, PhD …
Page with Layout
Bakin Lab Research Focus
… Working with co-author and Roswell Park colleague Christos Fountzilas, MD, FACP , the Bakin Lab investigated DNA repair … ) Roswell Park research funding NCI R37 Merit Award (Dr. Fountzilas, PI) We discovered that p53-mutant cancer cells … Working with co-author and Roswell Park colleague Christos Fountzilas, MD, FACP , the Bakin Lab investigated DNA repair …
Clinical Trial
A Phase 2 Clinical Trial of Nalirifox as Neoadjuvant Treatment for Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma
… Borderline Resectable Pancreatic Ductal Adenocarcinoma II Fountzilas, Christos This phase II trial tests how well …